Amorfix Life Science (ARFXF) 0.1001 $ARFXF ProM
Post# of 273249
Posted On: 09/26/2016 7:10:17 AM
Amorfix Life Science (ARFXF) 0.1001 $ARFXF
ProMIS Neurosciences to Present at CNS Diseases World Summit 2016
PRWeb - Wed Sep 14, 6:04AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"
today announced that the Company has been invited to present at GTCBio's CNS Diseases World Summit 2016 to be held at the Hyatt Boston Harbor on September 12-15, 2016 in Boston, MA.
ProMIS Neurosciences announces positive validation of novel antibody therapeutic candidates for Alzheimer's disease
PRWeb - Tue Sep 13, 6:07AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that at least three of its antibody therapeutic candidates targeting prion-like strains of Amyloid beta (Aβ) have successfully completed validation in cadaveric brain tissue and cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). The successful product candidates demonstrated the desired target profile of binding to brain tissue extracts and CSF from AD patients while not binding to plaque, as evidenced by microscopic examination (immunohistochemistry) of AD brain tissue. These monoclonal antibody (mAb) therapeutics have been designed to selectively bind only to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Aβ, which are widely believed to play a key role in the development and progression of AD.
ProMIS Neurosciences to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PRWeb - Mon Sep 12, 6:09AM CDT
ProMIS™ Neurosciences, Inc.
ProMIS Neurosciences Announces Second Quarter 2016 Results
PRWeb - Fri Aug 12, 6:05AM CDT
Recent Corporate Highlights
ProMIS Neurosciences' Chief Science Officer Dr. Neil Cashman Presenting as an Invited Speaker at the 2016 Zing Propagation in Neurodegenerative Disease Conference
PRWeb - Thu Aug 11, 6:06AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that its Chief Science Officer Dr. Neil Cashman is presenting today as an invited speaker at the Zing Propagation in Neurodegenerative Disease Conference held in Dublin, Ireland between August 8-11, 2016. Dr. Cashman's oral presentation is entitled "Prion-like Propagation of SOD1 Misfolding in Amyotrophic Lateral Sclerosis (ALS)".
ProMIS Neurosciences Reports Highlights from the 2016 Alzheimer's Association International Conference
PRWeb - Wed Aug 03, 6:10AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today reported highlights from the recent Alzheimer's Association International Conference (AAIC) meeting, held in Toronto, Canada, from July 23 to 28, 2016.
ProMIS Neurosciences Announces Results in Two Presentations at the 2016 Alzheimer's Association International Conference
PRWeb - Thu Jul 28, 6:05AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced results in two presentations on its recent therapeutic developments at the Alzheimer's Association International Conference on July 27th, 2016 in Toronto, Ontario, Canada.
ProMIS Neurosciences Announces Identification of Multiple Product Candidates Targeting Alzheimer's Disease
PRWeb - Thu Jun 02, 6:09AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" , a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer's disease (AD). These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aβ), which are widely believed to play a key role in the development and progression of AD.
ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease
CNW Group - Thu Jun 02, 6:00AM CDT
Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of misfolded Amyloid beta
PMN.TO: 0.14 (+0.01)
ProMIS Neurosciences Announces First Quarter 2016 Results
PRWeb - Wed May 11, 6:10AM CDT
Recent Corporate Highlights
ProMIS Neurosciences announces first quarter 2016 results
CNW Group - Wed May 11, 6:00AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company" today announced its operational and financial results for the three months ended March 31, 2016.
PMN.TO: 0.14 (+0.01)
ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease
CNW Group - Thu May 05, 6:00AM CDT
Novel target is fourth in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.14 (+0.01)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 3.27 (-0.03), DRNA: 4.23 (-0.07), INCY: 88.98 (-0.29), LLY: 81.16 (-0.13), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ANTH: 3.19 (+0.05), EXEL: 14.89 (+0.15)
ProMIS Neurosciences to Present at CNS Diseases World Summit 2016
PRWeb - Wed Sep 14, 6:04AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"
today announced that the Company has been invited to present at GTCBio's CNS Diseases World Summit 2016 to be held at the Hyatt Boston Harbor on September 12-15, 2016 in Boston, MA. ProMIS Neurosciences announces positive validation of novel antibody therapeutic candidates for Alzheimer's disease
PRWeb - Tue Sep 13, 6:07AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that at least three of its antibody therapeutic candidates targeting prion-like strains of Amyloid beta (Aβ) have successfully completed validation in cadaveric brain tissue and cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). The successful product candidates demonstrated the desired target profile of binding to brain tissue extracts and CSF from AD patients while not binding to plaque, as evidenced by microscopic examination (immunohistochemistry) of AD brain tissue. These monoclonal antibody (mAb) therapeutics have been designed to selectively bind only to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Aβ, which are widely believed to play a key role in the development and progression of AD. ProMIS Neurosciences to Present at Rodman & Renshaw 18th Annual Global Investment Conference
PRWeb - Mon Sep 12, 6:09AM CDT
ProMIS™ Neurosciences, Inc.
ProMIS Neurosciences Announces Second Quarter 2016 Results
PRWeb - Fri Aug 12, 6:05AM CDT
Recent Corporate Highlights
ProMIS Neurosciences' Chief Science Officer Dr. Neil Cashman Presenting as an Invited Speaker at the 2016 Zing Propagation in Neurodegenerative Disease Conference
PRWeb - Thu Aug 11, 6:06AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that its Chief Science Officer Dr. Neil Cashman is presenting today as an invited speaker at the Zing Propagation in Neurodegenerative Disease Conference held in Dublin, Ireland between August 8-11, 2016. Dr. Cashman's oral presentation is entitled "Prion-like Propagation of SOD1 Misfolding in Amyotrophic Lateral Sclerosis (ALS)". ProMIS Neurosciences Reports Highlights from the 2016 Alzheimer's Association International Conference
PRWeb - Wed Aug 03, 6:10AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today reported highlights from the recent Alzheimer's Association International Conference (AAIC) meeting, held in Toronto, Canada, from July 23 to 28, 2016. ProMIS Neurosciences Announces Results in Two Presentations at the 2016 Alzheimer's Association International Conference
PRWeb - Thu Jul 28, 6:05AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced results in two presentations on its recent therapeutic developments at the Alzheimer's Association International Conference on July 27th, 2016 in Toronto, Ontario, Canada. ProMIS Neurosciences Announces Identification of Multiple Product Candidates Targeting Alzheimer's Disease
PRWeb - Thu Jun 02, 6:09AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer's disease (AD). These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aβ), which are widely believed to play a key role in the development and progression of AD. ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease
CNW Group - Thu Jun 02, 6:00AM CDT
Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of misfolded Amyloid beta
PMN.TO: 0.14 (+0.01)
ProMIS Neurosciences Announces First Quarter 2016 Results
PRWeb - Wed May 11, 6:10AM CDT
Recent Corporate Highlights
ProMIS Neurosciences announces first quarter 2016 results
CNW Group - Wed May 11, 6:00AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"
today announced its operational and financial results for the three months ended March 31, 2016. PMN.TO: 0.14 (+0.01)
ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease
CNW Group - Thu May 05, 6:00AM CDT
Novel target is fourth in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.14 (+0.01)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 3.27 (-0.03), DRNA: 4.23 (-0.07), INCY: 88.98 (-0.29), LLY: 81.16 (-0.13), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ANTH: 3.19 (+0.05), EXEL: 14.89 (+0.15)
(0)
(0)Scroll down for more posts ▼